Premature babies with Respiratory Distress Syndrome (RDS) have difficulty breathing, that if untreated results in 100% mortality. FlowLite, our nCPAP (neonatal continuous positive air pressure) device, will ensure high-quality newborn RDS treatment is within most countries' capacity to implement and save more newborn babies' lives.